Availability: In StockBiological Description:KRN633 is a potent and selective VEGFR inhibitor. which inhibits tyrosine phosphorylation of VEGFR-2 (IC50 = 1.16 nmol/L) in human umbilical vein endothelial cells. Selectivity profiling with recombinant tyrosine kinases showed that KRN633 is highly selective for VEGFR-1, -2, and -3. KRN633 inhibits tumor growth in several in vivo tumor xenograft models with diverse tissue origins, including lung, colon, and prostate, in athymic mice and rats. KRN633 also causes the regression of some well-established tumors and those that had regrown after the cessation of treatment. KRN633 was well tolerated and had no significant effects on body weight or the general health of the animals. KRN633 might be useful in the treatment of solid tumors and other diseases that depend on pathologic angiogenesis.Purity: >98.00%Molecular formula: C₂₀H₂₁ClN₄O₄ Molecular Weight: 446.90Storage Instructions: Two years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSOReferences: for more information, please visit images/AffixScientific/

Affix Scientific国烟草货号： 1185887-21-1生物学描述：AB-FUBINACA是一种基于吲唑的合成大麻素（CB），其对中央CB1受体的亲和力（Ki = 0.9 nM）比JWH 018高10倍。AB-FUBINACA最初是由辉瑞公司（Pfizer，Inc.）合成的。一种有效的CB1受体调节剂，可用于潜在的治疗用途，但最近在非法草药产品中与AB-PINACA一起被发现。1,2AB-CHMINACA与AB-FUBINACA在结构上相关，但环己基取代了4-氟苯基。该化合物的生理和毒理特性尚未确定。该产品用于研究和法医应用。纯度： ≥98％分子式： C 2 0 H 2 8 N 4O 2分子量： 129.15贮存说明： -20°C粉末，2周DMSO中4°C，6个月-DMSO中80°C，2年